What guidance did Veru's management provide for the next earnings period?

What factors drove the changes in Veru's revenue and profit?

What is the revenue and EPS growth rate for Veru year over year?

What is Veru's latest dividend and current dividend yield?

Did Veru beat or miss consensus estimates last quarter?

What is Veru's gross profit margin?

What were the key takeaways from Veru's earnings call?

What does Veru do and what are its main business segments?

- **FDA-Backed Dual Pathways**: Enobosarm can seek approval via 5% incremental weight loss or preservation of physical function, with validated 3mg dosage.
- **PLATEAU Study Launched**: 200-patient trial to assess enobosarm's ability to break weight loss plateau with semaglutide; interim analysis at 34 weeks for lean/fat mass trends.
- **Financial Stability**: $33M cash balance post-public offering, supporting operations through key interim analysis.
- **Strategic Focus**: Enobosarm's dual potential to enhance weight loss quality and preserve bone density positions it for differentiated obesity treatment.

**【CEO Summary Section】**
- **Enobosarm Regulatory Clarity**: FDA provided two pathways for approval: 5% incremental weight loss over 52 weeks or preservation of physical function if weight loss is less than 5%. Enobosarm 3mg dosage is validated for future trials.
- **Phase IIb PLATEAU Study Initiation**: Double-blind, placebo-controlled study with 200 older obese patients to evaluate enobosarm + semaglutide for breaking weight loss plateau. Primary endpoint: 68-week weight loss; interim analysis at 34 weeks for lean/fat mass changes.
- **Bone Density Impact**: FDA validated hip BMD as a surrogate endpoint for osteoporosis. Enobosarm preclinical data shows potential to counter GLP-1-induced BMD loss, offering an alternative approval pathway.

**【CFO Financial Commentary】**
- **Q1 2026 Financials**: Net loss of $5.3M ($0.26/diluted share) vs. $8.9M prior year. R&D expenses decreased to $1.3M (down from $5.7M) due to winding down QUALITY study. G&A expenses reduced to $4.1M (from $5.2M) due to lower share-based compensation.
- **Cash Position**: $33M as of Dec 31, 2025 (vs. $15.8M prior quarter), sufficient to fund operations through PLATEAU interim analysis. Public offering in Oct 2025 raised $23.4M net proceeds.

**【Q&A Key Highlights】**
- **Semaglutide Choice**: Injectable semaglutide selected for PLATEAU to replicate QUALITY study conditions; oral form may bridge to Phase III. FDA feedback supports using stair climb test as functional endpoint.
- **Functional Endpoint Validation**: FDA accepts stair climb test ( unloaded and loaded) to measure physical function. Patient-reported outcomes will complement objective measures.
- **Interim Analysis Design**: No futility analysis; interim focuses on lean/fat mass trends to guide Phase III planning. Primary endpoint remains 68-week weight loss.
- **Approval Pathway Flexibility**: If <5% incremental weight loss, statistically significant functional benefit could support approval. BMD preservation offers alternative endpoint.

Veru Inc. (VERU) Q1 2026 Earnings Call Transcript

- **Enobosarm Phase IIb Success**: 65.4% of patients achieved ≥5% weight loss with 100% lean mass preservation, vs. 47.4% on GLP-1 alone.
- **New Trial Targeting Weight Loss Plateau**: PLATEAU trial to evaluate breaking GLP-1 plateaus in ≥65-year-olds, with 72-week weight loss endpoint.
- **Regulatory Flexibility**: FDA allows 5% incremental weight loss or physical function improvement as primary endpoints.
- **Financial Strength**: $39.2M cash post-offering; R&D spend up 22% to $15.6M.

**【CEO Summary Section】**
- Enobosarm Phase IIb QUALITY trial met primary endpoint, preserving 100% lean mass vs. placebo, with 12% greater fat loss and 65.4% of patients achieving ≥5% weight loss. Maintenance phase showed enobosarm monotherapy reduced weight regain by 46%.
- Phase IIb PLATEAU trial to begin Q1 2026, targeting BMI ≥35, ≥65-year-olds on GLP-1 receptor agonists. Primary endpoint: 72-week weight loss; interim DEXA scan at 36 weeks.
- FDA guidance allows for 5% incremental weight loss or clinically significant physical function improvement as primary endpoints for Phase III.
- IP portfolio extended to 2043+ with new enobosarm formulation patents.

**【CFO Financial Commentary】**
- FY2025 net loss: $15.7M ($1.07/diluted share). R&D: $15.6M (+22% vs. prior year). Cash post-public offering: $39.2M (including $23.4M from Q4 2025 offering).
- Sold FC2 business for $16.5M, reducing liabilities by $9.9M. Proceeds from ENTADFI asset sales: $8.3M.
- Cash runway sufficient for PLATEAU interim analysis (Q1 2027).

Veru Inc. (VERU) Q4 2025 Earnings Call Transcript

- **Clinical Success**: Enobosarm preserved 100% lean mass and reduced weight regain by 46% in Phase IIb, with FDA Phase III design feedback expected Q3 2025.
- **New Formulation**: Patented modified release enobosarm (IP to 2046) enables potential fixed-dose GLP-1 combinations.
- **Financial Update**: $15M cash, net loss $7.3M, Phase III capital needs ~$40M pending FDA clarity.
- **Strategic Focus**: Partnering with GLP-1 manufacturers and targeting older adults with obesity for first indication.

**【CEO Summary Section】**
- **Enobosarm Phase IIb Results**: Enobosarm + semaglutide preserved 100% of lean mass (p < 0.001) and achieved 42% greater fat loss (6mg dose, p = 0.017) vs placebo. 17.6% of 3mg group experienced stair climb decline vs 44.8% placebo (59.8% reduction, p = 0.006). Maintenance phase showed 46% weight regain reduction (3mg, p = 0.038) with 100% fat preservation.
- **New Modified Release Formulation**: Demonstrated delayed Tmax, reduced Cmax, and similar AUC to IR. Patented through 2046, with potential for fixed-dose combinations with oral GLP-1s.
- **FDA Meeting & Phase III Design**: End-of-Phase II meeting scheduled Q3 2025 to discuss Phase III design targeting older adults (>60) with obesity. Proposed endpoint: preservation of lean mass & physical function (stair climb test). FDA may seek broader patient inclusion beyond 60+.
- **Partnership Strategy**: Actively engaging with GLP-1 manufacturers (e.g., Novo, Lilly) and big pharma for ex-US partnerships, leveraging enobosarm's unique IP and combination potential.

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: Net loss of $7.3M ($0.50/diluted share) vs $10.3M prior quarter. R&D expenses down 37.5% ($3M vs $4.8M) due to Phase IIb completion. Cash balance $15M as of June 30, 2025, with $4.2M change of control payment to SWK Holdings.
- **Liquidity Outlook**: Current cash insufficient for 12-month operations, but sufficient to fund through FDA Phase II meeting. Phase III capital needs ~$40M (400-patient trial estimate).

**【Q&A Key Highlights】**
- **Formulation Safety & Efficacy**: Modified release shows better safety profile (lower Cmax) while maintaining efficacy (similar AUC). FDA will review bioavailability data in Phase III design.
- **FDA Feedback Expectations**: Likely focus on endpoint validation (physical function vs weight loss) and potential expansion to younger populations. No open-label extension needed for safety.
- **Market Opportunity**: 41.5% of Medicare Part D patients >60 could benefit; 34.4% have sarcopenic obesity. Enobosarm's ability to prevent GLP-1-induced muscle loss positions it for broad chronic weight management use.
- **Capital Needs**: CEO estimates $40M for Phase III, but final cost will depend on FDA feedback. Seeking nondilutive funding via partnerships.

Veru Inc. (VERU) Q3 2025 Earnings Call Transcript

- **Breakthrough Obesity Data**: Enobosarm + GLP-1 achieved 99% fat loss, 71% muscle preservation, and 62% reduction in functional decline.\n- **Phase 3 Readiness**: FDA meeting Q3 2025; modified-release formula in Phase 1.\n- **Financial Watch**: $20M cash runway; seeking partnerships to fund Phase 3 ($30-40M estimated cost).\n- **Key Risk**: 60% of GLP-1 users stop therapy due to fat regain; enobosarm aims to address this unmet need.\n

**【CEO Overview】**
- Enobosarm Phase 2b trial demonstrated 71% preservation of lean body mass vs placebo, with 99% fat loss at 3mg dose (p < 0.001).\n- Patients on enobosarm + semaglutide saw 62.4% reduction in functional decline (Stair Climb test), vs 42.6% decline in placebo group.\n- Phase 2b extension study to assess fat regain post-GLP-1 discontinuation expected Q2 2025.\n- Modified-release enobosarm formulation in Phase 1, targeting 2025 Phase 3 readiness.\n- FDA End-of-Phase 2 meeting scheduled Q3 2025 to discuss Phase 3 design.\n
**【CFO Financial Highlights】**
- Q2 2025 R&D expenses: $3.9M (vs $3M prior quarter), driven by Enobosarm trial costs.\n- SG&A: $5.2M (vs $5.9M prior quarter), down 12% due to lower share-based comp.\n- Net loss: $7.9M ($0.05/diluted share) vs $8.7M ($0.06) prior quarter.\n- Cash balance: $20M as of March 31, 2025, sufficient for ~9 months of operations.\n- FY25 cash runway dependent on FDA Phase 3 clarity and potential partnerships.\n
**【Q&A Key Takeaways】**
- **Partnership Strategy**: Actively engaging with large pharma for non-dilutive funding; Phase 2b data positions enobosarm as GLP-1 "muscle preservation enabler".\n- **Phase 3 Design**: 400-patient trial targeting older adults (>60yo) with obesity; primary endpoint: Stair Climb power at 24 weeks.\n- **Safety Profile**: No new safety signals; mild, transient ALT elevations consistent with prior studies.\n- **Competitive Differentiation**: Oral SARM vs IV myostatin inhibitors; 99% fat loss vs 50% in GLP-1 monotherapy.\n- **Tariff Risk**: Minimal impact; enobosarm sourced from low-cost manufacturers with <10% COGS.\n

Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

- **Enobosarm Breakthrough**: Phase 2b data shows 99% fat-selective weight loss vs. 68% on semaglutide alone, with 54% reduction in physical function decline (p=0.0049). FDA-endorsed Phase 3 planned for H2 2025.
- **Sabizabulin Innovation**: Novel anti-inflammatory agent for atherosclerosis with >260-patient safety profile; FDA-approved Phase 2 design targeting coronary plaque regression.
- **Financial Strength**: $26.6M cash post-FC2 sale, with no near-term funding gaps. Modified-release enobosarm formulation in preclinical trials for 2025 Phase 3.
- **Strategic Focus**: Divested non-core assets to prioritize high-value cardiometabolic pipeline, with key enobosarm data readouts in Q2 2025.

**【CEO Summary Section】**
- **Enobosarm Phase 2b QUALITY Study Success**: Achieved statistically significant preservation of lean mass (71% relative reduction in lean loss vs. placebo, p=0.002) and enhanced fat loss (46% greater fat loss at 6mg dose, p=0.014). Patients on enobosarm + semaglutide lost 99.1% fat vs. 68% fat on semaglutide alone. Physical function decline (stair climb power) was reduced by 54.4% (p=0.0049) in the enobosarm group.
- **Sabizabulin Expansion**: Exploring as a novel anti-inflammatory agent for atherosclerotic cardiovascular disease, with Phase 2 design approved by FDA targeting coronary plaque regression via CT angiography.
- **FC2 Sale**: Sold FDA-approved FC2 female condom business for $18M, enabling focus on biopharma pipeline. Proceeds to support clinical trials.
- **Phase 3 Planning**: Enobosarm Phase 3 expected to be 52-week study, leveraging modified-release oral formulation for commercialization.

**【CFO Financial Highlights】**
- **Q1 2025 Financials**: 
  - Total revenue: $1.7M (down from $2.6M prior quarter due to FC2 discontinuation).
  - R&D expenses: $5.7M (up $4.3M for enobosarm Phase 2b).
  - SG&A: $5.2M (down 23% due to headcount reduction).
  - Net loss: $1.8M (vs. $7.7M prior quarter) with $26.6M cash on hand.
- **FC2 Sale Impact**: Net proceeds $16.4M after costs, with $4.2M loss on sale. Terminated $12.8M residual royalty liability, recognizing $8.6M gain on debt extinguishment.
- **Liquidity**: Current cash sufficient for operations through end-2025, with key enobosarm data readouts (Phase 2b extension Q2 2025) fully funded.

**【Q&A Key Takeaways】**
- **Extension Trial Insights**: 13% dropout rate due to GLP-1-related GI side effects. FDA IDMC approved continuation after reviewing full safety dataset.
- **Sabizabulin Differentiation**: Unlike colchicine, sabizabulin has stable PK, no major drug-drug interactions, and >260 patients in safety database. Phase 2 coronary artery disease study expected H2 2026.
- **Partnership Potential**: Exploring fixed-dose combo with oral GLP-1 agonists due to enobosarm's oral bioavailability and complementary mechanism.
- **Market Expansion**: FDA agrees sarcopenic obesity exists in younger populations; Phase 3 design may include younger cohorts as observational subgroup.


Veru Inc (VERU) Q1 2025 Earnings Call Transcript

Veru (VERU)-8 Aug 24-2024 Q3 Earnings call transcript

Veru (VERU)-8 May 24-2024 Q2 Earnings call transcript

Veru (VERU)-8 Feb 24-2024 Q1 Earnings call transcript

- **Breast Cancer Breakthrough**: Enobosarm Phase 3 trial shows early promise with 2 partial responses in first 3 patients; potential accelerated approval if ORR exceeds 30%.
- **Viral ARDS Expansion**: Sabizabulin's 55% mortality reduction in COVID-19 trial positions it for broader ARDS indication, with FDA meeting in September.
- **FC2 Commercial Surge**: 115% Q3 growth in new prescriptions and U.S. public sector sales, driving $6.3M net income despite pipeline challenges.
- **Financial Stability**: $16.2M cash + $14M Entadfi payments ensure >12-month runway, supported by reduced R&D and FC2 profitability.

**【CEO Summary Section】**
- **Oncology Pipeline Progress**: Enobosarm Phase 3 (Enabler-2) trial in metastatic breast cancer has entered Stage 1 with five treatment arms, targeting objective tumor response rate (ORR) as the primary endpoint. Early data from the first three patients showed two partial responses and stable disease, with no safety issues.
- **Viral ARDS Program Update**: Sabizabulin's Phase 3 COVID-19 trial demonstrated a 55.2% relative reduction in mortality. The company plans to expand the trial to include all viral-induced ARDS (e.g., influenza, RSV) and meet with FDA in September for regulatory clarity. Preclinical data shows Sabizabulin's anti-inflammatory activity in influenza-induced ARDS.
- **Commercial Success**: FC2 female condom prescriptions grew 115% Q3 2023, with 4,400 new prescriptions. U.S. public sector sales increased 115% YoY, driven by partnerships like Access Group Services. Global public sector sales are supported by a multi-year South African tender and potential Brazil tender later in 2023.

**【CFO Financial Commentary】**
- **Q3 2023 Financials**: Net revenue $3.3M (down 66% YoY) due to loss of pill club business, but U.S. public sector sales grew 115% YoY. Operating expenses decreased 52% YoY to $13.8M, driven by reduced R&D ($15.2M YoY decline). Net income $6.3M ($0.07/diluted share) vs. net loss $22.2M YoY, driven by $17.5M gain from Entadfi sale.
- **Cash Position**: $16.2M as of June 30, 2023, plus $14M from Entadfi promissory notes. CFO expects cash runway for >12 months, supported by FC2 growth and reduced OpEx.

**【Q&A Highlights】**
- **Enabler-2 Trial Strategy**: CEO expects ORR for Enobosarm monotherapy to be ~30% vs. 4-5% for active control. If Stage 1 meets statistical significance, FDA may allow accelerated approval with confirmatory Phase 3 for progression-free survival.
- **Sabizabulin Expansion**: Company plans to propose a Phase 3 trial for all viral-induced ARDS, targeting 408 patients with interim analyses for early efficacy signals. BARDA may include Sabizabulin in a large ARDS trial with 200+ subjects per arm.
- **FC2 Growth**: CFO notes 115% Q3 growth in new prescriptions and 115% YoY increase in U.S. public sector sales. Brazil tender expected late 2023, with potential 20-50M unit orders.
- **Cash Flexibility**: CFO confirms ability to extend runway beyond 12 months via FC2 growth, Entadfi payments, and reduced R&D spend.


Actual										-0.1	-0.5	-1.7	2.3	-0.4	-0.3	-0.5	-0.8	-1.8	-2.8	-5.1	-4.6	-4.8	0.7	-0.8	-0.7	-0.7	-0.6	-0.6	-0.5	-0.5	0.05	-0.26
Forecast										-0.425	-0.325	-0.3667	-0.475	-0.38	-0.6	-0.92	-0.94	-1.42	-1.6	-3.025	-3.7667	-3.325	-2.0333	-1.2	-0.5333	-0.58	-0.74	-0.76	-0.625	-0.534	-0.365	-0.472
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+76.47%	-53.85%	-363.59%	+584.21%	-5.26%	+50.00%	+45.65%	+14.89%	-26.76%	-75.00%	-68.60%	-22.12%	-44.36%	+134.43%	+33.33%	-31.26%	-20.69%	+18.92%	+21.05%	+20.00%	+6.37%	+113.70%	+44.92%

Actual	--	--	--	--	--	--	--	--	--	9.94M	10.32M	11.75M	14.62M	13.34M	17.66M	15.65M	14.14M	13.03M	9.60M	2.59M	2.51M	6.59M	3.34M	2.10M	4.10M	3.95M	6.66M	0	0	0	0	0
Forecast	--	--	--	--	--	--	--	--	--	10.97M	10.74M	10.61M	10.92M	14.29M	14.10M	18.17M	13.84M	12.21M	16.67M	11.55M	5.07M	4.33M	6.21M	3.90M	3.00M	3.50M	3.56M	3.02M	725.00K	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-9.37%	-3.86%	+10.77%	+33.84%	-6.64%	+25.20%	-13.88%	+2.12%	+6.72%	-42.39%	-77.59%	-50.50%	+52.28%	-46.24%	-46.15%	+36.67%	+12.97%	+86.99%	-100.00%	-100.00%	0.00%	0.00%	0.00%

VERU

VERU fundamentals

VERU Q1 2026 Earnings

Earnings Call

You can ask Aime

VERU

VERU fundamentals

VERU Q1 2026 Earnings

Earnings Call

VERU Earnings Call Summary for Q1/20268:00 AM on Feb 11, 2026

VERU Earnings Call Summary for Q4/20258:00 AM on Dec 17, 2025

VERU Earnings Call Summary for Q3/20258:00 AM on Aug 12, 2025

VERU Earnings Call Summary for Q2/20258:00 AM on May 8, 2025

VERU Earnings Call Summary for Q1/20258:00 AM on Feb 13, 2025

You can ask Aime